Literature DB >> 23453906

How animal models of leukaemias have already benefited patients.

Julien Ablain1, Rihab Nasr, Jun Zhu, Ali Bazarbachi, Valérie Lallemand-Breittenbach, Hugues de Thé.   

Abstract

The relative genetic simplicity of leukaemias, the development of which likely relies on a limited number of initiating events has made them ideal for disease modelling, particularly in the mouse. Animal models provide incomparable insights into the mechanisms of leukaemia development and allow exploration of the molecular pillars of disease maintenance, an aspect often biased in cell lines or ex vivo systems. Several of these models, which faithfully recapitulate the characteristics of the human disease, have been used for pre-clinical purposes and have been instrumental in predicting therapy response in patients. We plea for a wider use of genetically defined animal models in the design of clinical trials, with a particular focus on reassessment of existing cancer or non-cancer drugs, alone or in combination.
Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23453906      PMCID: PMC5528420          DOI: 10.1016/j.molonc.2013.01.006

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  77 in total

1.  Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells.

Authors:  A Bazarbachi; M E El-Sabban; R Nasr; F Quignon; C Awaraji; J Kersual; L Dianoux; Y Zermati; J H Haidar; O Hermine; H de Thé
Journal:  Blood       Date:  1999-01-01       Impact factor: 22.113

2.  Revisiting the differentiation paradigm in acute promyelocytic leukemia.

Authors:  Julien Ablain; Hugues de The
Journal:  Blood       Date:  2011-03-28       Impact factor: 22.113

3.  15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia.

Authors:  J D Rowley; H M Golomb; C Dougherty
Journal:  Lancet       Date:  1977-03-05       Impact factor: 79.321

4.  The age incidence of chronic myeloid leukemia can be explained by a one-mutation model.

Authors:  Franziska Michor; Yoh Iwasa; Martin A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-25       Impact factor: 11.205

Review 5.  The theory of APL.

Authors:  F Piazza; C Gurrieri; P P Pandolfi
Journal:  Oncogene       Date:  2001-10-29       Impact factor: 9.867

Review 6.  How animal models of leukaemias have already benefited patients.

Authors:  Julien Ablain; Rihab Nasr; Jun Zhu; Ali Bazarbachi; Valérie Lallemand-Breittenbach; Hugues de Thé
Journal:  Mol Oncol       Date:  2013-02-11       Impact factor: 6.603

7.  How I treat acute promyelocytic leukemia.

Authors:  Martin S Tallman; Jessica K Altman
Journal:  Blood       Date:  2009-12-10       Impact factor: 22.113

Review 8.  High-throughput insertional mutagenesis screens in mice to identify oncogenic networks.

Authors:  Jaap Kool; Anton Berns
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

9.  All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.

Authors:  Zhi-Xiang Shen; Zhan-Zhong Shi; Jing Fang; Bai-Wei Gu; Jun-Min Li; Yong-Mei Zhu; Jing-Yi Shi; Pei-Zheng Zheng; Hua Yan; Yuan-Fang Liu; Yu Chen; Yang Shen; Wen Wu; Wei Tang; Samuel Waxman; Hugues De Thé; Zhen-Yi Wang; Sai-Juan Chen; Zhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-24       Impact factor: 11.205

10.  Genetic variegation of clonal architecture and propagating cells in leukaemia.

Authors:  Kristina Anderson; Christoph Lutz; Frederik W van Delft; Caroline M Bateman; Yanping Guo; Susan M Colman; Helena Kempski; Anthony V Moorman; Ian Titley; John Swansbury; Lyndal Kearney; Tariq Enver; Mel Greaves
Journal:  Nature       Date:  2010-12-15       Impact factor: 49.962

View more
  4 in total

1.  Modelling acute myeloid leukemia (AML): What's new? A transition from the classical to the modern.

Authors:  Annachiara Dozzo; Aoife Galvin; Jae-Won Shin; Santo Scalia; Caitriona M O'Driscoll; Katie B Ryan
Journal:  Drug Deliv Transl Res       Date:  2022-08-05       Impact factor: 5.671

Review 2.  In Vitro and In Vivo Modeling of Normal and Leukemic Bone Marrow Niches: Cellular Senescence Contribution to Leukemia Induction and Progression.

Authors:  Myriam Janeth Salazar-Terreros; Jean-Paul Vernot
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

Review 3.  How animal models of leukaemias have already benefited patients.

Authors:  Julien Ablain; Rihab Nasr; Jun Zhu; Ali Bazarbachi; Valérie Lallemand-Breittenbach; Hugues de Thé
Journal:  Mol Oncol       Date:  2013-02-11       Impact factor: 6.603

4.  Generation of Pediatric Leukemia Xenograft Models in NSG-B2m Mice: Comparison with NOD/SCID Mice.

Authors:  Anilkumar Gopalakrishnapillai; E Anders Kolb; Priyanka Dhanan; Aruna Sri Bojja; Robert W Mason; Diana Corao; Sonali P Barwe
Journal:  Front Oncol       Date:  2016-06-27       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.